STOCK TITAN

[Form 4] DENTSPLY SIRONA Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Liquidia Corporation (LQDA) – Form 4 insider transaction by CEO Roger Jeffs

The filing discloses two reportable events for the period 11-15 July 2025:

  • 13,833 common shares acquired on 11-Jul-2025 through the vesting and settlement of performance stock units (transaction code M). The PSUs were part of a 221,338-unit grant dated 11-Jan-2024.
  • 20,252 common shares sold on 14-Jul-2025 at $14.28 per share (transaction code S) under a Rule 10b5-1 trading plan. The sale was expressly for tax-withholding obligations linked to the earlier vesting of RSUs and PSUs.

After the transactions, Jeffs’ beneficial ownership stands at:

  • 1,038,560 shares held directly
  • 46,595 shares held indirectly via the Roger A. Jeffs Living Trust
  • 1,541,667 shares held indirectly through Serendipity BioPharma LLC

He also retains significant unvested equity incentives: 108,562 RSUs from a 2023 grant, 138,336 RSUs from a 2024 grant, and 229,327 RSUs from a 2025 grant.

The net change is a decrease of 6,419 shares (≈0.2 % of his total beneficial ownership) and generates proceeds of roughly $289 thousand. Given the small size relative to his >2.6 million share stake and the pre-arranged 10b5-1 plan, the filing appears routine and tax-related rather than a directional signal.

Liquidia Corporation (LQDA) – Transazione interna Form 4 del CEO Roger Jeffs

La comunicazione riporta due eventi rilevanti per il periodo 11-15 luglio 2025:

  • 13.833 azioni ordinarie acquisite l'11 luglio 2025 tramite il vesting e il regolamento di performance stock units (codice transazione M). Le PSU facevano parte di una concessione di 221.338 unità datata 11 gennaio 2024.
  • 20.252 azioni ordinarie vendute il 14 luglio 2025 a 14,28 $ per azione (codice transazione S) nell'ambito di un piano di trading Rule 10b5-1. La vendita è stata effettuata espressamente per adempiere a obblighi di ritenuta fiscale legati al precedente vesting di RSU e PSU.

Dopo queste operazioni, la proprietà effettiva di Jeffs risulta:

  • 1.038.560 azioni detenute direttamente
  • 46.595 azioni detenute indirettamente tramite il Roger A. Jeffs Living Trust
  • 1.541.667 azioni detenute indirettamente tramite Serendipity BioPharma LLC

Conserva inoltre significativi incentivi azionari non ancora maturati: 108.562 RSU da una concessione 2023, 138.336 RSU da una concessione 2024 e 229.327 RSU da una concessione 2025.

La variazione netta è una diminuzione di 6.419 azioni (circa lo 0,2% della sua proprietà totale) e genera un ricavo di circa 289 mila $. Considerata la piccola entità rispetto al suo patrimonio superiore a 2,6 milioni di azioni e il piano 10b5-1 predefinito, la comunicazione sembra di natura ordinaria e fiscale piuttosto che un segnale di direzione.

Liquidia Corporation (LQDA) – Transacción interna Formulario 4 por el CEO Roger Jeffs

El informe revela dos eventos reportables para el período del 11 al 15 de julio de 2025:

  • 13,833 acciones comunes adquiridas el 11 de julio de 2025 mediante la consolidación y liquidación de unidades de acciones por desempeño (código de transacción M). Las PSUs formaban parte de una concesión de 221,338 unidades fechada el 11 de enero de 2024.
  • 20,252 acciones comunes vendidas el 14 de julio de 2025 a $14.28 por acción (código de transacción S) bajo un plan de negociación Rule 10b5-1. La venta se realizó expresamente para cubrir obligaciones de retención de impuestos vinculadas al vesting previo de RSUs y PSUs.

Después de estas transacciones, la propiedad beneficiaria de Jeffs es:

  • 1,038,560 acciones en propiedad directa
  • 46,595 acciones en propiedad indirecta a través del Roger A. Jeffs Living Trust
  • 1,541,667 acciones en propiedad indirecta a través de Serendipity BioPharma LLC

También mantiene incentivos accionarios significativos aún no consolidados: 108,562 RSUs de una concesión 2023, 138,336 RSUs de una concesión 2024 y 229,327 RSUs de una concesión 2025.

El cambio neto es una disminución de 6,419 acciones (≈0.2 % de su propiedad total) y genera ingresos aproximados de $289 mil. Dado el tamaño reducido en relación con su participación superior a 2.6 millones de acciones y el plan preestablecido 10b5-1, el informe parece rutinario y relacionado con impuestos más que una señal direccional.

Liquidia Corporation (LQDA) – CEO Roger Jeffs의 Form 4 내부자 거래

해당 보고서는 2025년 7월 11일부터 15일까지 두 건의 신고 대상 거래를 공개합니다:

  • 2025년 7월 11일에 13,833 보통주 취득 (거래 코드 M) – 성과 주식 단위(PSU)의 베스팅 및 정산을 통해 취득. 해당 PSU는 2024년 1월 11일에 부여된 221,338 단위 중 일부입니다.
  • 2025년 7월 14일에 20,252 보통주 매도 (거래 코드 S) – 주당 $14.28에 Rule 10b5-1 거래 계획에 따라 매도. 이 매도는 이전 RSU 및 PSU 베스팅에 따른 세금 원천징수 의무를 충족하기 위한 것입니다.

거래 후 Jeffs의 실질 소유 지분은 다음과 같습니다:

  • 직접 보유 주식 1,038,560주
  • Roger A. Jeffs Living Trust를 통한 간접 보유 46,595주
  • Serendipity BioPharma LLC를 통한 간접 보유 1,541,667주

또한 2023년 부여된 108,562 RSU, 2024년 부여된 138,336 RSU, 2025년 부여된 229,327 RSU 등 상당한 미베스팅 주식 인센티브도 보유하고 있습니다.

순 변화는 6,419주 감소(전체 실질 소유 지분의 약 0.2%)이며, 약 $289,000의 수익을 발생시켰습니다. 그의 260만 주 이상의 보유 지분과 사전 계획된 10b5-1 플랜을 고려할 때, 이번 신고는 방향성 신호보다는 일상적이고 세금 관련 거래로 보입니다.

Liquidia Corporation (LQDA) – Transaction Form 4 d’initié par le CEO Roger Jeffs

Le dépôt révèle deux événements déclarables pour la période du 11 au 15 juillet 2025 :

  • 13 833 actions ordinaires acquises le 11 juillet 2025 via l’acquisition et la liquidation d’unités d’actions de performance (code transaction M). Ces PSU faisaient partie d’une attribution de 221 338 unités datée du 11 janvier 2024.
  • 20 252 actions ordinaires vendues le 14 juillet 2025 au prix de 14,28 $ par action (code transaction S) dans le cadre d’un plan de négociation Rule 10b5-1. La vente a été réalisée expressément pour satisfaire des obligations de retenue fiscale liées au vesting antérieur de RSU et PSU.

Après ces transactions, la détention effective de Jeffs s’élève à :

  • 1 038 560 actions détenues directement
  • 46 595 actions détenues indirectement via le Roger A. Jeffs Living Trust
  • 1 541 667 actions détenues indirectement via Serendipity BioPharma LLC

Il conserve également d’importants incitatifs en actions non acquis : 108 562 RSU d’une attribution 2023, 138 336 RSU d’une attribution 2024 et 229 327 RSU d’une attribution 2025.

Le changement net est une diminution de 6 419 actions (≈0,2 % de sa détention totale effective) et génère un produit d’environ 289 000 $. Étant donné la faible taille par rapport à sa participation de plus de 2,6 millions d’actions et le plan 10b5-1 préétabli, le dépôt semble être une opération de routine liée à la fiscalité plutôt qu’un signal directionnel.

Liquidia Corporation (LQDA) – Form 4 Insider-Transaktion des CEO Roger Jeffs

Die Meldung offenbart zwei meldepflichtige Ereignisse für den Zeitraum 11. bis 15. Juli 2025:

  • 13.833 Stammaktien erworben am 11. Juli 2025 durch die Zuteilung und Abrechnung von Performance-Aktieneinheiten (Transaktionscode M). Die PSUs waren Teil einer Zuteilung von 221.338 Einheiten vom 11. Januar 2024.
  • 20.252 Stammaktien verkauft am 14. Juli 2025 zu 14,28 $ pro Aktie (Transaktionscode S) im Rahmen eines Rule 10b5-1 Handelsplans. Der Verkauf erfolgte ausdrücklich zur Erfüllung von steuerlichen Abzugsverpflichtungen im Zusammenhang mit dem vorherigen Vesting von RSUs und PSUs.

Nach den Transaktionen beläuft sich Jeffs’ wirtschaftliches Eigentum auf:

  • 1.038.560 Aktien direkt gehalten
  • 46.595 Aktien indirekt über den Roger A. Jeffs Living Trust gehalten
  • 1.541.667 Aktien indirekt über Serendipity BioPharma LLC gehalten

Er hält außerdem bedeutende noch nicht ausgeübte Aktienanreize: 108.562 RSUs aus einer Zuteilung von 2023, 138.336 RSUs aus einer Zuteilung von 2024 und 229.327 RSUs aus einer Zuteilung von 2025.

Die Nettoveränderung ist ein Rückgang um 6.419 Aktien (≈0,2 % seines gesamten wirtschaftlichen Eigentums) und generiert Erlöse von etwa 289.000 $. Angesichts der geringen Größe im Verhältnis zu seinem Bestand von über 2,6 Millionen Aktien und des vorab vereinbarten 10b5-1-Plans erscheint die Meldung routinemäßig und steuerlich bedingt und weniger als ein richtungsweisendes Signal.

Positive
  • Executive continues to hold a sizable stake – over 2.6 million shares after the transactions, aligning interests with shareholders.
  • Acquisition of 13,833 shares via PSU vesting indicates ongoing realization of performance-based equity awards.
Negative
  • Net decrease of 6,419 shares due to tax-related sale, though immaterial in percentage terms.

Insights

TL;DR: Minor, tax-driven share sale; negligible impact on insider sentiment.

The Form 4 shows Roger Jeffs settling 13,833 PSUs, then selling 20,252 shares to cover taxes. Net ownership dipped by only 6,419 shares, leaving him with >1 million directly held shares and >2.6 million in total when trusts and LLC holdings are included. Because the S-coded transaction was executed under a Rule 10b5-1 plan, it was scheduled in advance and is unlikely to reflect a change in outlook. The scale—<0.3 % of his aggregate position—suggests minimal market impact. Overall, the filing is best interpreted as routine housekeeping rather than a bullish or bearish signal.

Liquidia Corporation (LQDA) – Transazione interna Form 4 del CEO Roger Jeffs

La comunicazione riporta due eventi rilevanti per il periodo 11-15 luglio 2025:

  • 13.833 azioni ordinarie acquisite l'11 luglio 2025 tramite il vesting e il regolamento di performance stock units (codice transazione M). Le PSU facevano parte di una concessione di 221.338 unità datata 11 gennaio 2024.
  • 20.252 azioni ordinarie vendute il 14 luglio 2025 a 14,28 $ per azione (codice transazione S) nell'ambito di un piano di trading Rule 10b5-1. La vendita è stata effettuata espressamente per adempiere a obblighi di ritenuta fiscale legati al precedente vesting di RSU e PSU.

Dopo queste operazioni, la proprietà effettiva di Jeffs risulta:

  • 1.038.560 azioni detenute direttamente
  • 46.595 azioni detenute indirettamente tramite il Roger A. Jeffs Living Trust
  • 1.541.667 azioni detenute indirettamente tramite Serendipity BioPharma LLC

Conserva inoltre significativi incentivi azionari non ancora maturati: 108.562 RSU da una concessione 2023, 138.336 RSU da una concessione 2024 e 229.327 RSU da una concessione 2025.

La variazione netta è una diminuzione di 6.419 azioni (circa lo 0,2% della sua proprietà totale) e genera un ricavo di circa 289 mila $. Considerata la piccola entità rispetto al suo patrimonio superiore a 2,6 milioni di azioni e il piano 10b5-1 predefinito, la comunicazione sembra di natura ordinaria e fiscale piuttosto che un segnale di direzione.

Liquidia Corporation (LQDA) – Transacción interna Formulario 4 por el CEO Roger Jeffs

El informe revela dos eventos reportables para el período del 11 al 15 de julio de 2025:

  • 13,833 acciones comunes adquiridas el 11 de julio de 2025 mediante la consolidación y liquidación de unidades de acciones por desempeño (código de transacción M). Las PSUs formaban parte de una concesión de 221,338 unidades fechada el 11 de enero de 2024.
  • 20,252 acciones comunes vendidas el 14 de julio de 2025 a $14.28 por acción (código de transacción S) bajo un plan de negociación Rule 10b5-1. La venta se realizó expresamente para cubrir obligaciones de retención de impuestos vinculadas al vesting previo de RSUs y PSUs.

Después de estas transacciones, la propiedad beneficiaria de Jeffs es:

  • 1,038,560 acciones en propiedad directa
  • 46,595 acciones en propiedad indirecta a través del Roger A. Jeffs Living Trust
  • 1,541,667 acciones en propiedad indirecta a través de Serendipity BioPharma LLC

También mantiene incentivos accionarios significativos aún no consolidados: 108,562 RSUs de una concesión 2023, 138,336 RSUs de una concesión 2024 y 229,327 RSUs de una concesión 2025.

El cambio neto es una disminución de 6,419 acciones (≈0.2 % de su propiedad total) y genera ingresos aproximados de $289 mil. Dado el tamaño reducido en relación con su participación superior a 2.6 millones de acciones y el plan preestablecido 10b5-1, el informe parece rutinario y relacionado con impuestos más que una señal direccional.

Liquidia Corporation (LQDA) – CEO Roger Jeffs의 Form 4 내부자 거래

해당 보고서는 2025년 7월 11일부터 15일까지 두 건의 신고 대상 거래를 공개합니다:

  • 2025년 7월 11일에 13,833 보통주 취득 (거래 코드 M) – 성과 주식 단위(PSU)의 베스팅 및 정산을 통해 취득. 해당 PSU는 2024년 1월 11일에 부여된 221,338 단위 중 일부입니다.
  • 2025년 7월 14일에 20,252 보통주 매도 (거래 코드 S) – 주당 $14.28에 Rule 10b5-1 거래 계획에 따라 매도. 이 매도는 이전 RSU 및 PSU 베스팅에 따른 세금 원천징수 의무를 충족하기 위한 것입니다.

거래 후 Jeffs의 실질 소유 지분은 다음과 같습니다:

  • 직접 보유 주식 1,038,560주
  • Roger A. Jeffs Living Trust를 통한 간접 보유 46,595주
  • Serendipity BioPharma LLC를 통한 간접 보유 1,541,667주

또한 2023년 부여된 108,562 RSU, 2024년 부여된 138,336 RSU, 2025년 부여된 229,327 RSU 등 상당한 미베스팅 주식 인센티브도 보유하고 있습니다.

순 변화는 6,419주 감소(전체 실질 소유 지분의 약 0.2%)이며, 약 $289,000의 수익을 발생시켰습니다. 그의 260만 주 이상의 보유 지분과 사전 계획된 10b5-1 플랜을 고려할 때, 이번 신고는 방향성 신호보다는 일상적이고 세금 관련 거래로 보입니다.

Liquidia Corporation (LQDA) – Transaction Form 4 d’initié par le CEO Roger Jeffs

Le dépôt révèle deux événements déclarables pour la période du 11 au 15 juillet 2025 :

  • 13 833 actions ordinaires acquises le 11 juillet 2025 via l’acquisition et la liquidation d’unités d’actions de performance (code transaction M). Ces PSU faisaient partie d’une attribution de 221 338 unités datée du 11 janvier 2024.
  • 20 252 actions ordinaires vendues le 14 juillet 2025 au prix de 14,28 $ par action (code transaction S) dans le cadre d’un plan de négociation Rule 10b5-1. La vente a été réalisée expressément pour satisfaire des obligations de retenue fiscale liées au vesting antérieur de RSU et PSU.

Après ces transactions, la détention effective de Jeffs s’élève à :

  • 1 038 560 actions détenues directement
  • 46 595 actions détenues indirectement via le Roger A. Jeffs Living Trust
  • 1 541 667 actions détenues indirectement via Serendipity BioPharma LLC

Il conserve également d’importants incitatifs en actions non acquis : 108 562 RSU d’une attribution 2023, 138 336 RSU d’une attribution 2024 et 229 327 RSU d’une attribution 2025.

Le changement net est une diminution de 6 419 actions (≈0,2 % de sa détention totale effective) et génère un produit d’environ 289 000 $. Étant donné la faible taille par rapport à sa participation de plus de 2,6 millions d’actions et le plan 10b5-1 préétabli, le dépôt semble être une opération de routine liée à la fiscalité plutôt qu’un signal directionnel.

Liquidia Corporation (LQDA) – Form 4 Insider-Transaktion des CEO Roger Jeffs

Die Meldung offenbart zwei meldepflichtige Ereignisse für den Zeitraum 11. bis 15. Juli 2025:

  • 13.833 Stammaktien erworben am 11. Juli 2025 durch die Zuteilung und Abrechnung von Performance-Aktieneinheiten (Transaktionscode M). Die PSUs waren Teil einer Zuteilung von 221.338 Einheiten vom 11. Januar 2024.
  • 20.252 Stammaktien verkauft am 14. Juli 2025 zu 14,28 $ pro Aktie (Transaktionscode S) im Rahmen eines Rule 10b5-1 Handelsplans. Der Verkauf erfolgte ausdrücklich zur Erfüllung von steuerlichen Abzugsverpflichtungen im Zusammenhang mit dem vorherigen Vesting von RSUs und PSUs.

Nach den Transaktionen beläuft sich Jeffs’ wirtschaftliches Eigentum auf:

  • 1.038.560 Aktien direkt gehalten
  • 46.595 Aktien indirekt über den Roger A. Jeffs Living Trust gehalten
  • 1.541.667 Aktien indirekt über Serendipity BioPharma LLC gehalten

Er hält außerdem bedeutende noch nicht ausgeübte Aktienanreize: 108.562 RSUs aus einer Zuteilung von 2023, 138.336 RSUs aus einer Zuteilung von 2024 und 229.327 RSUs aus einer Zuteilung von 2025.

Die Nettoveränderung ist ein Rückgang um 6.419 Aktien (≈0,2 % seines gesamten wirtschaftlichen Eigentums) und generiert Erlöse von etwa 289.000 $. Angesichts der geringen Größe im Verhältnis zu seinem Bestand von über 2,6 Millionen Aktien und des vorab vereinbarten 10b5-1-Plans erscheint die Meldung routinemäßig und steuerlich bedingt und weniger als ein richtungsweisendes Signal.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Campion Simon D

(Last) (First) (Middle)
C/O DENTSPLY SIRONA INC
13320-B BALLANTYNE CORPORATE PLACE

(Street)
CHARLOTTE NC 28277

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President, CEO & Member of BOD
3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/11/2025 A 1,260.911(1) A $0 272,403.9801(2)(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock (Supplemental Executive Retirement Plan) SERP (4) 07/11/2025 A 131.3974(5) (4) (4) Common Stock 131.3974 $16.2 13,353.196 D
Explanation of Responses:
1. Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.
2. Includes 370 shares acquired between January 1st - June 30, 2025 under the Dentsply Sirona Employee Stock Purchase Plan.
3. Includes 1,178.392 shares acquired through dividend reinvestment on 7/10/2025.
4. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting persons termination of employment.
5. Comprised of phantom stock acquired as a result of accrued dividends.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Jessica Causey, Attorney-In-Fact for Simon D. Campion 07/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Liquidia (LQDA) shares did CEO Roger Jeffs sell in July 2025?

Jeffs sold 20,252 shares on 14-Jul-2025 at $14.28 per share.

What was the reason for the LQDA share sale disclosed in this Form 4?

The shares were sold solely to cover taxes arising from the settlement of previously granted RSUs and PSUs.

How many Liquidia shares does Roger Jeffs now own?

He owns 1,038,560 shares directly and 1,588,262 shares indirectly, totaling ≈2.63 million.

Was the July 2025 sale part of a pre-arranged trading plan?

Yes. The transaction was executed under a Rule 10b5-1 plan adopted on 15-Dec-2023.

Did the CEO acquire any new Liquidia shares in this period?

Yes, 13,833 shares were acquired on 11-Jul-2025 through PSU conversion (code M).
Dentsply Sirona Inc

NASDAQ:XRAY

XRAY Rankings

XRAY Latest News

XRAY Latest SEC Filings

XRAY Stock Data

3.31B
198.48M
0.45%
106.2%
4.05%
Medical Instruments & Supplies
Dental Equipment & Supplies
Link
United States
CHARLOTTE